Name: UMIN ID:
Unique ID issued by UMIN | UMIN000006252 |
---|---|
Receipt number | R000007398 |
Scientific Title | A randomized phase III trial of adjuvant gefitinib versus cisplatin and vinorelbine in completely resected (stage II-III) non-small cell lung cancer (NSCLC) patients with mutated EGFR (investigator-initiated multicenter clinical trial) |
Date of disclosure of the study information | 2011/09/03 |
Last modified on | 2022/01/06 20:06:31 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2011/08/30 18:51:57 | ||
2 | Update | 2011/09/01 13:02:10 | TEL TEL |
|
3 | Update | 2011/09/15 10:31:26 | Recruitment status |
|
4 | Update | 2011/10/21 10:44:17 | Email |
|
5 | Update | 2013/04/01 09:48:06 | Name of person sending information Name of person sending information |
|
6 | Update | 2013/04/04 19:16:54 | Email1 |
|
7 | Update | 2014/04/30 15:11:58 | Key exclusion criteria Key exclusion criteria |
|
8 | Update | 2014/04/30 15:32:28 | Organization Organization Division name Division name Address Address TEL Name of person sending information Name of person sending information |
|
9 | Update | 2015/03/30 17:14:29 | Email1 |
|
10 | Update | 2016/02/16 16:50:55 | Recruitment status |
|
11 | Update | 2016/03/31 09:26:59 | Email1 |
|
12 | Update | 2016/09/02 10:32:36 | Name of primary person or sponsor Organization |
|
13 | Update | 2019/09/05 10:31:20 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Address Last name of contact person Last name of contact person Zip code Address Address Organization Organization Address Address Tel |
|
14 | Update | 2019/09/05 10:32:05 | Number of participants that the trial has enrolled |
|
15 | Update | 2019/09/05 10:32:56 | Date of IRB Last follow-up date |
|
16 | Update | 2020/07/31 10:32:30 | Address Address |
|
17 | Update | 2021/03/26 13:59:46 | Recruitment status |
|
18 | Update | 2022/01/06 20:06:31 | URL releasing protocol Publication of results URL related to results and publications Results Results Results date posted Date of the first journal publication of results Baseline Characteristics Baseline Characteristics Participant flow Participant flow Adverse events Adverse events Outcome measures Outcome measures |